Literature DB >> 28215980

A special article following the relicence of aprotinin injection in Europe.

David Royston1, Stefan De Hert2, Jan van der Linden3, Alexandre Ouattara4, Kai Zacharowski5.   

Abstract

Keywords:  Aprotinin; Benefit-Risk analysis; Conditions of use; Nordic Aprotinin Patient Registry (NAPaR); Relicense

Mesh：

Substances：

Year:  2017        PMID： 28215980     DOI： 10.1016/j.accpm.2017.02.001

Source DB:  PubMed          Journal:  Anaesth Crit Care Pain Med        ISSN： 2352-5568            Impact factor:   4.132


× No keyword cloud information.
  3 in total

1.  Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.

Authors:  Irene de Miguel; Josune Orbe; Juan A Sánchez-Arias; José A Rodríguez; Agustina Salicio; Obdulia Rabal; Miriam Belzunce; Elena Sáez; Musheng Xu; Wei Wu; Haizhong Tan; Hongyu Ma; José A Páramo; Julen Oyarzabal
Journal:  ACS Med Chem Lett       Date:  2018-04-16       Impact factor: 4.345

2.  Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo.

Authors:  Eun-Jung Song; Erica Españo; Sang-Mu Shim; Jeong-Hyun Nam; Jiyeon Kim; Kiho Lee; Song-Kyu Park; Chong-Kil Lee; Jeong-Ki Kim
Journal:  Sci Rep       Date:  2021-05-03       Impact factor: 4.379

3.  Use and safety of aprotinin in routine clinical practice: A European postauthorisation safety study conducted in patients undergoing cardiac surgery.

Authors:  Stefan De Hert; Alexandre Ouattara; David Royston; Jan van der Linden; Kai Zacharowski
Journal:  Eur J Anaesthesiol       Date:  2022-06-29       Impact factor: 4.183
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.